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showing Gram-positive specific antimicrobial activity of TBBPA (7) led us to further study this 41 activity against common pathogens, focusing on in vitro and in vivo antibacterial activity against 42 SA. The primary objective of this study was to evaluate the use of TBBPA as a treatment for 43 bacterial infection. 44
In the susceptibility studies, the common pathogens Enterococcus faecium, Staphylococcus aureus, 45
Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa and Escherichia coli 46 were tested. TBBPA selectively exerted antimicrobial effects against Gram-positive bacteria, 47 consistent with our previous findings (7). TBBPA inhibited the in vitro growth of SA and MRSA at 48 a concentration of 4 or 2 µg/mL, respectively (Table 1 ). These common strains are known as the 49 "ESKAPE" pathogens, which cause the majority of hospital infections in the US, with MRSA 50 infection leading to identifiable skin and soft-tissue infections in US hospitals (8, 9). These results 51 indicate that TBBPA is a valuable antibacterial agent, with high specific activity against 52
Gram-positive pathogens. 53
We evaluated the development of antimicrobial resistance to TBBPA in SA. SA was cultured for 54 40 days with daily transfers in the presence of antibiotics (concentrations were constant or 55 increased stepwise). The minimum inhibitory concentrations (MICs) of ampicillin (AMP) and 56 chloramphenicol (CHL) against SA increased rapidly and AMP-or CHL-resistant SA was 57 established with a MIC increase of 25-or 12-fold, respectively. In contrast, we were unable to 58 obtain TBBPA-resistant SA in the presence of a low concentration (4×MIC) of TBBPA. Serial 59 passage of SA in the presence of sub-level MIC of TBBPA for 40 days failed to produce highlyresistant strains (Fig. 1) , indicating a lower development of resistance to TBBPA compared with 61
AMP and CHL. 62
Gram-positive and Gram-negative bacteria have distinct differences in cell wall structure, leading 63 to the possibility that the specific antimicrobial activity of TBBPA may relate to the presence of 64 teichoic acid in the peptidoglycan layer. This led us to try to understand the mechanism of 65 antimicrobial activity by analyzing changes in cell wall morphology using scanning and 66 transmission electron microscopy (SEM and TEM). TBBPA exposure resulted in loss of normal 67 cell morphology with significant cracks in the cell envelope ( Fig. 2. 
2). Control cells had an intact 68
cell envelope with protoplasts inside (Fig. 2.1, 2. 3). TBBPA-treated cells showed significant 69 protoplast leakage through the cell envelope ( Fig. 2.4) , formation of a mesosome-like structure 70 These results demonstrated that TBBPA may exhibit antimicrobial effects by inducing cell wall 75 damage, affecting cell membrane stability. 76
Therapeutics against bacterial infections are limited and development of novel therapeutics to treat 77 drug-resistant infections has been a concern, as many pathogens are resistant to most currently 78 available antibacterial agents. Therefore, the development of efficient antimicrobial agents with a 79 low incidence of resistance is urgently needed. Animal models of skin infection are important 80 tools to elucidate the potential of new antimicrobials to prevent or reduce the severity of infection 81 (11). We investigated whether TBBPA was effective as an antimicrobial against SA using an in 82 vivo skin infection model. We assessed the effect of TBBPA on SA-induced pathological changes 83 in the skin and determined the number of viable SA cells in skin wounds. Wounds were excised on 84 day 11 and the number of viable SA cells present in the tissue was determined (Fig. 3B ). There 85 were significant differences in viable SA cell numbers isolated from fester and exudates in the 86 wound tissue. Viable SA cell numbers were significantly reduced when mice were treated with 87 TBBPA or AMP, compared with untreated mice. AMP and TBBPA treatment significantly reduced 88 bacterial load, which was measured using the plate count method (Fig. 3F) . Wound closure of 89 vehicle control did not change over the 7 day test period. Treatment with TBBPA resulted inobvious wound recovery (Fig. 3A and B) and significantly reduced the CFUs of SA, similar to the 91 outcome of AMP treatment. Thus, TBBPA could be used as a treatment for SA-induced skin 92
infections. Histological examination of the wound tissue revealed neutrophil infiltration and 93 epithelialization in different treatment groups. Treatment with TBBPA resulted in a significant 94 thinning of the epidermis layer and less dissociated epithelial cells in dermis layer (Fig. 4) . The 95 increase in epithelialization suggests that the recovery process may have been delayed. Untreated 96 infections showed significant epithelialization on day 11, having a thicker epithelial layer 97 compared with normal skin tissue. TBBPA demonstrated good in vivo activity in a mouse skin 98 infection model which was comparable to antibiotics in some cases; the inflammatory response of 99 the epidermis and muscle cells caused by SA was significantly reduced by TBBPA treatment. 100
Overall, these results were consistent with the hypothesis that TBBPA exhibits in vivo 101
antimicrobial activity and provides protection against SA skin infection. 102
The safety of TBBPA was first explored in mice. Upon 5 mg/kg TBBPA administration, no 103 obvious adverse effects on body weight, feeding behavior, and physical activity of the mice were 104 observed. This indicated that a low dose of TBBPA was not toxic and relatively safe. Acute dermal, 105 oral and inhalation toxicity of TBBPA has been tested. The results showed that TBBPA exhibited 106 low acute toxicity by multiple exposure routes (dermal LD 50 > 10,000 mg/kg in rabbits, oral LD 50 > 107 5,000 mg/kg in rats and inhalation LD 50 > 10,000 mg/m 3 in rats and mice). TBBPA does not cause 108 skin, eye or respiratory irritation in humans or tested animals (12, 13). Chronic and sub-chronic 109 toxicity studies of TBBPA show that it has a low hazard concern (13). Upon dietary exposure of 110 TBBPA for 70 days in Wistar rats, no significant changes in reproduction were observed. TBBPA 111 doses up to 3,000 mg/kg caused no histopathological changes in the organs assessed (14). In a 112 two-generation toxicity study with doses of 0, 10, 100 or 1000 mg/kg/day TBBPA in Sprague 113
Dawley rats, no obvious effects on reproduction, fertility, or developmental toxicity were observed. 114 TBBPA shows low acute toxicity in mice, with an LD 50 > 20 g/kg (15). With an NOAEL of 1,000 115 mg/kg, administration of 5 mg/kg TBBPA for 3 days should be relatively safe (13). No apparent 116 physiological changes were observed in mice treated with 5 mg/kg TBBPA by gavage for 3 days 117 (data not shown), adding evidence to the hypothesis that short-term exposure to a low dose of 118 TBBPA should be safe. 119
This study evaluated the in vivo antimicrobial effects of TBBPA in a murine model of SA skin 120 infection. We found that administration of TBBPA significantly reduced bacterial counts in the 121 wound compared with vehicle, demonstrating the potential of this compound as a novel 122
antimicrobial. The relative low MIC values of TBBPA suggest that this compound has potential as 123 a candidate for the treatment of skin infections caused by SA in vivo. Ultimately, this compound 124 may lead to specific therapeutic approaches to target SA infectious diseases. New compounds 125 could be designed based on the structure of TBBPA, making modifications to improve the safety, 126 bioavailability and treatment efficacy. Additional work is needed to further elucidate the specific 127 antimicrobial mechanism of TBBPA and its application in skin infection therapy. 137  138  139  140  141  142  143  144  145  146  147  148  149  150  151  152  153  154  155  156 
